Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

VOLTADOL FORTE 23,2 MG/G GEL - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/VOLTADOL FORTE 23,2 MG/G GEL

Approved

STANDARD

VOLTADOL FORTE 23,2 MG/G GEL

Glaxosmithkline Consumer Healthcare S.R.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Dec 14, 2023
Approval ID: a213f8a580e8b962
Company: Glaxosmithkline Consumer Healthcare S.R.L.
Type: Standard

Approval Details

Approval Id: a213f8a580e8b962
Drug Cima Aemps Name: VOLTADOL FORTE 23,2 MG/G GEL
Register Number: 13380-2020-01-24IP
Holder Company Name: Glaxosmithkline Consumer Healthcare S.R.L.
Marketing Company Name: Elam Pharma Labs S.L.
Authorization Date: 2023-12-14
Dosage Form: GEL
Dose: 23,2 mg/g
Route Of Administration: USO CUTÁNEO
Prescription Type: Sin Receta
Commercialized: No
Company Name: Glaxosmithkline Consumer Healthcare S.R.L.

Active Ingredients

DICLOFENACO DIETILAMINA

23.2 mg/g

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Dec 14, 2023

Approval ID

a213f8a580e8b962

Type

Standard

Back to CIMA-AEMPS Approvals